DOCSLIB.ORG

Comparative Review of Oral Hypoglycemic Agents in Adults

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparative Review of Oral Hypoglycemic Agents in Adults SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms: ............................................................................................................................................................................... 3 I. Background and Rationale for the review: ....................................................................................................................... 4 II. Medications under comparative review: ......................................................................................................................... 4 Table 1 - New oral hypoglycemic agents for comparison with current EML agents .......................................................... 5 III. Literature searches and methodology: ............................................................................................................................ 5 1. Title Search Results: .................................................................................................................................................... 6 2. Statement about quality of evidence: ........................................................................................................................ 6 IV. Clinical efficacy and safety evaluation: ............................................................................................................................ 6 1. DPP-4 Inhibitors (Sitagliptin, Saxagliptin) and Metformin: ......................................................................................... 6 2. Glitazones (Rosiglitazone, Pioglitazone) and Metformin: ........................................................................................... 7 3. Alpha-glucosidase inhibitors (AGIs – Acarbose, Miglitol) and Metformin: ................................................................. 8 4. Meglitinides (Repaglinide, Nateglinide) and Metformin: ........................................................................................... 8 5. DPP-4 Inhibitors (Sitagliptin, Saxagliptin) and Sulfonylureas:..................................................................................... 9 6. Glitazones (Rosiglitazone, Pioglitazone) and Sulfonylureas: ...................................................................................... 9 7. Alpha-glucosidase inhibitors (AGIs – Acarbose, Miglitol) and Sulfonylureas: .......................................................... 10 8. Meglitinides (Repaglinide, Nateglinide) and Sulfonylureas: .................................................................................... 10 9. Statement on Amylin Analogues – Pramlintide: ....................................................................................................... 11 V. Cost, Regulatory and Current NEML Availability Evaluation: ......................................................................................... 11 Table 2: Comparative Cost Chart and Drug Approval by US and Australian Regulatory Agencies ................................... 12 Table 3: Oral hypoglycemics listed on selected NEMLs .................................................................................................... 12 VI. Summary: ....................................................................................................................................................................... 12 Appendix: .............................................................................................................................................................................. 14 Table 4: Summary: Comparative efficacy and safety of oral hypoglycemics .................................................................... 14 Table 5: Chart of systematic reviews used ....................................................................................................................... 15 Table 6: Question: Should Metformin vs DPP-4 Inhibitors be used for Diabetes Mellitus, Type 2? ................................ 16 Table 7: Question: Should Metformin vs Glitazones be used for Diabetes Mellitus Type 2? .......................................... 19 Table 8: Question: Should Acarbose vs Metformin be used for Diabetes Mellitus, Type 2? ........................................... 22 Table 9: Question: Should Metformin vs meglitinides be used for Diabetes Mellitus, Type 2? ....................................... 25 Table 10: Question: Should Glitazones vs SFU be used for Diabetes Mellitus, Type 2? ................................................... 28 Table 11: Question: Should Acarbose vs be used in SFU? ................................................................................................ 31 Table 12: Question: Should SFU vs meglitinides be used for Diabetes Mellitus, Type 2? ................................................ 34 References: ........................................................................................................................................................................... 36 Page 2 of 37 Acronyms: AGI - Alpha-glucosidase inhibitor AHRQ – Agency for Healthcare Research and Quality CHF – Congestive heart failure CI – Confidence interval CV – Cardiovascular DM – Diabetes Mellitus DPP-4 inhibitors – dipeptidylpeptidase-4 inhibitors EC – Expert Committee EML – Essential Medicines List FDA – Food and Drug Administration GRADE – Grading of Recommendations Assessment, Development and Evaluation HbA1c – Glycosylated hemoglobin HDL – High density lipoprotein-cholesterol LDL – Low density lipoprotein-cholesterol LMICs - Low- and Middle-Income Countries MSH – Management Sciences for Health NEML – National Essential Medicines List RCT – Randomized controlled trial SFU – Sulfonylureas TG – Triglycerides TGA – Therapeutics Goods Administration US – United States of America USD – United States dollar WHO – World Health Organization Page 3 of 37 I. Background and Rationale for the review: Diabetes mellitus is a chronic disease that requires life-long pharmacological and non-pharmacological management to prevent complications such as cardiovascular disease, retinopathy, nephropathy, and neuropathy.[1, 2] While type 2 diabetes mellitus is the most common form of diabetes comprising of 90% to 95% of all diabetes cases.[2] An estimated 346 million people worldwide live with diabetes, resulting in 3.4 million deaths in 2004, with more than 80% of these deaths occurring in low- and middle income countries.[3] It is projected that the death burden from diabetes will double by the year 2030.[3] According to the 2010 WHO report on NCDs, the estimated prevalence of diabetes in 2008 was about 8% for men and women in low-income countries and 10% for both sexes in upper-middle-income countries with the highest global prevalence of diabetes in Eastern Mediterranean Region and Region of the Americas.[4] The high prevalence rate is of concern since diabetes in the leading cause of renal failure, visual impairment and blindness and increases the risk of lower limb amputation by at least 10 times.[4] Additionally, patients living with diabetes may need 2 to 3 three times the health-care resources compared to people without diabetes and diabetes care may require allocation of up to 15% of national health care budgets.[4] Furthermore, given the close link between poverty and NCDs, the NCDs impose a disproportionate burden on low and middle income countries.[4] In the United States, 11 classes of medications are approved for management of DM; these include 8 oral agents such as – biguanides, sulfonylureas, meglitinides, thiazolidinediones (glitazones), alpha- glucosidase inhibitors, DPP-4 inhibitors, bile acid sequestrants, dopamine-2 agonists, and 3 injectable agents such as – GLP-1 receptor agonists (incretins), amylin analogues and insulin.[1, 5] The 18th WHO expert committee on the selection and use of essential medicines in 2011 requested a review of the current oral hypoglycemic medicines for use in adult to determine if updates to the EML are needed. [6] Currently, the EML contains two oral hypoglycemics, glibenclamide (sulfonylurea) and metformin. This document will conduct comparative analysis of four oral hypoglycemic agents – glitazones (thiazolidinediones), DPP-4 inhibitors, alpha-glucosidase inhibitors and meglitinides versus sulfonylureas (SFU) and metformin to determine their efficacy and safety, as well as conduct a cost- comparison. This review will also provide an overview of the current availability of the four agents in questions in LMICs by surveying NEMLs of 15 nations at random; as well as provide information on regulatory status of these agents in the US and Australia. The regulatory status in US and Australia was selected as an initial reference point given the stringent review and approval process required for therapeutic approval by these agencies and due to the availability of the databases in English. II. Medications under comparative review: Table 1 lists the medications reviewed by this document and the comparisons made. The 18th EC on the Selection and Use of Essential Medicines had also requested a review on pramlintide – this medication was not reviewed; a statement regarding this therapeutic peptide is made in section IV-9. Page 4 of 37 Table 1 - New oral hypoglycemic agents for comparison with current EML agents Comparison # EML Medication Comparison Medication GRADE Table Comparison 1 Metformin DPP-4 Inhibitors (Sitagliptin) Table 6 Comparison 2 Glitazones (Pioglitazone, Rosiglitazone) Table 7 Comparison
Load more

Recommended publications
  • Treatment of Diabetes Mellitus
    TREATMENT OF DIABETES MELLITUS DIABETES is a condition that affects how the body makes energy from food. Food is broken down into sugar (glucose) in the body and released into the blood. When the blood sugar level rises after a meal, insulin responds to let the sugar into the cells to be used as energy. In diabetes, the body either does not make enough insulin or it stops responding to insulin as well as it should. This results in sugar staying in the blood and leads to serious health problems over time. DIAGNOSIS OF DIABETES1 • A1C Test: Lab test measuring average blood sugar over past two to three months • Fasting Blood Sugar Test: Lab test measuring blood sugar after eight hours of no food or drink • Oral Glucose Tolerance Test (OGTT): Measures blood sugar before and two hours after drinking a specific sugary liquid • Random Blood Sugar Test: Measures blood sugar at a moment in time, without any kind of preparation (like fasting) FASTING BLOOD ORAL GLUCOSE TOLERANCE RANDOM BLOOD RESULT A1C TEST SUGAR TEST TEST SUGAR TEST Diabetes ≥ 6.5% ≥126 mg/dL ≥ 200 mg/dL ≥ 200 mg/dL Prediabetes 5.7 – 6.4% 100 – 125 mg/dL 140 – 199 mg/dL N/A Normal < 5.7% ≤99 mg/dL < 140 mg/dL N/A NON-DRUG TREATMENTS2 THERAPY COST WHAT TO EXPECT Diet (Mediterranean diet) and exercise (30 minutes a day, five days a week of moderate- Weight loss $-$$ intensity exercise); 7% weight loss decreases risk of diabetes3 Psychological intervention $$-$$$ Psychotherapy may reduce diabetic distress and improve glycemic control4,5 nationalcooperativerx.com PRESCRIPTION TREATMENTS
    [Show full text]
  • 295-304 Research Article Pulsatile Drug Delivery of Chitosan Co
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2015, 7(12):295-304 ISSN : 0975-7384 Research Article CODEN(USA) : JCPRC5 Pulsatile drug delivery of chitosan coated beads of miglitol with fast dissolving glimepiride tablet Bhise S. H.*, Surve B. S., Aloorkar N. H., Majumdar S. H. and Kulkarni A. S. Department of Pharmaceutics, Satara College of Pharmacy, Satara, Shivaji University, Maharashtra, India _____________________________________________________________________________________________ ABSTRACT : Pulsatile drug delivery system was developed which have three parts fast dissolving tablet of glimepiride, sustained release chitosan coated microbeads of miglitol and plug of HPMC E5 and spray dried lactose. After pre- formulation studies fast dissolving tablets were prepared by direct compression method; which shows instant drug release and % CDR of glimepiride fast dissolving tablet was found to be 70.81%. polymer plug have lag time 2.30 hr, chitosan coated miglitol beads shows sustained release upto 81.66% .this system is evaluated using different physicochemical parameters and in-vitro studies. Result suggests that the system can be applicable for diabetes treatment. Key words: Pulsatile, microbeads, sustained release, miglitol, glimepiride. _____________________________________________________________________________________________ INTRODUCTION Oral controlled drug delivery systems represent the most popular form of controlled drug delivery system which release the drug with constant or variable release rates.[1] Dose of drug, reduced dosage frequency, avoidance of side effects, and improved patient compliance. However, there are certain conditions for which such a release pattern is not suitable. These conditions demand release of drug after a lag time. In other words, it is required that the drug should not be released at all during the initial phase of dosage form administration.
    [Show full text]
  • Effect of the Α-Glucosidase Inhibitor Miglitol on the Glucose Profile in Japanese Type 2 Diabetic Patients Receiving Multiple Daily Insulin Injections
    Endocrine Journal 2012, 59 (4), 345-352 ORIGINAL Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections Hiroyuki Kato, Akio Ohta, Suzuko Kobayashi, Satoshi Ishii, Yukiyoshi Sada, Hidetoshi Kobayashi, Shintaro Ohmori, Akihiko Kondo, Takuyuki Katabami, Junro Fuse, Hisashi Fukuda, Yoshio Nagai and Yasushi Tanaka Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan Abstract. Strict postprandial glycemic control may have a preventive effect on atherogenesis in patients with type 2 diabetes. The α-glucosidase inhibitor (α-GI) miglitol is useful for controlling the early postprandial increase of glucose, but the combined effect of miglitol and multiple daily insulin injections (MDI) on glucose excursion has not been evaluated. First, we retrospectively compared the daily glucose profile, evaluated by self-monitoring of blood glucose (SMBG) at nine times on the day before discharge from hospital, between type 2 diabetic patients receiving MDI (n=81) or MDI plus miglitol at 150 mg daily (n=24). Second, we prospectively examined the effect of adding miglitol to MDI on the daily glucose profile (SMBG) in 19 other type 2 diabetic patients. Although the daily insulin dosage and the glucose level before meals did not differ between the two groups, the 1-h postprandial glucose level after each meal, 2-h glucose level after lunch and dinner, mean and standard deviation of glucose, and amplitude of glucose excursion were significantly lower or smaller in the MDI plus miglitol group than in the MDI group.
    [Show full text]
  • Hypoglycemia in Diabetes: Common, Often Unrecognized
    REVIEW ILAN GABRIELY, MD HARRY SHAMOON, MD CME Diabetes Research Center, Albert Einstein Professor of Medicine, Diabetes Research CREDIT College of Medicine, New York Center, Albert Einstein College of Medicine, New York Hypoglycemia in diabetes: Common, often unrecognized ■ ABSTRACT YPOGLYCEMIA poses a major barrier to H diabetes treatment. On one hand, we Hypoglycemic episodes in patients with diabetes often go want to maintain tight glycemic control to unrecognized, and over time, patients may lose the ability prevent the vascular complications of diabetes, to sense hypoglycemia, increasing their risk. Intensive but we also have to ensure the safety and com- diabetes control is beneficial for patients with diabetes, fort of the patient by avoiding hypoglycemia— but it increases their risk of hypoglycemia, underscoring and by recognizing and treating it if it occurs. the complexity of diabetes management. Hypoglycemic events are probably com- mon, especially in patients with type 1 diabetes. ■ KEY POINTS And when patients with type 2 diabetes receive insulin, they may become more prone to hypo- Epinephrine release during hypoglycemia becomes glycemic episodes. Unfortunately, the more progressively defective in type 1 diabetes. This decrease in episodes of hypoglycemia a patient has, the epinephrine response is accompanied by an attenuated more the body’s response is blunted, decreasing autonomic neural response, which results in the clinical the patient’s awareness of an episode. syndrome of impaired awareness of hypoglycemia (ie, Thus, we need to be vigilant in monitor- lack of the warning symptoms of prevailing ing patients for increasing episodes of hypo- glycemia, and for events that a patient may not hypoglycemia).
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Women with Higher BMI at Lower Risk for Glaucoma
    44 WOMEN'S HEALTH SEPTEMBER 1, 2010 • FAMILY PRACTICE NEWS DRUGS, PREGNANCY, AND LACTATION Use of Antidiabetic Agents During Pregnancy n a previous column, I looked at the abinese), tolazamide (Tolinase), and tolbu- thetic analogue of human amylin given was discovered. No developmental toxi- ways uncontrolled hyperglycemia tamide (Orinase). They can cause marked by subcutaneous injection, but the ani- city was observed in the newborns. Iduring pregnancy causes significant and persistent neonatal hypoglycemia if mal data suggest moderate risk (struc- Pioglitazone (Actos) and rosiglitazone toxicity for the mother, embryo, fetus, taken close to birth. To prevent this toxi- tural anomalies in rats). The drug— (Avandia), thiazolidinediones used as ad- newborn, and adolescent (“Toxicity of city, therapy should be changed to insulin which slows the rate of gastric emptying, juncts to diet and exercise, lower insulin Diabetes in Pregnancy,” December in the third trimester or, at least, several prevents a postprandial rise in plasma resistance but do not promote insulin re- 2009, p. 52). days before birth. glucagon, and promotes satiety—is best lease. Animal reproduction data suggest This column examines the The second-generation sul- avoided in pregnancy. risk, but the human experience is too use of antidiabetic agents, fonylureas glipizide (Glu- Saxagliptin (Onglyza) and sitagliptin limited to assess the risk, so they should other than insulin, that are cotrol), glimepiride (Amaryl), (Januvia), inhibitors of the enzyme be avoided in pregnancy. used for non–insulin-depen- and glyburide (DiaBeta, Gly- dipeptidyl peptidase–4, are indicated as In summary, only metformin and gly- dent diabetes during preg- nase, and Micronase) are pre- monotherapy or in combination with buride have sufficient human pregnancy nancy and lactation.
    [Show full text]
  • (KPIC) PPO and Out-Of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier
    Kaiser Permanente Insurance Company (KPIC) PPO and Out-of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier This Drug Formulary was updated: September 1, 2021 NOTE: This drug formulary is updated often and is subject to change. Upon revision, all previous versions of the drug formulary are no longer in effect. This document contains information regarding the drugs that are covered when you participate in the California Nongrandfathered PPO and Out-of- Area Indemnity (OOA) Health Insurance Plans with specialty drug tier offered by Kaiser Permanente Insurance Company (KPIC) and fill your prescription at a MedImpact network pharmacy. Access to the most current version of the Formulary can be obtained by visiting kp.org/kpic-ca-rx-ppo-ngf. For help understanding your KPIC insurance plan benefits, including cost sharing for drugs under the prescription drug benefit and under the medical benefit, please call 1-800-788-0710 or 711 (TTY) Monday through Friday, 7a.m. to 7p.m. For help with this Formulary, including the processes for submitting an exception request and requesting prior authorization and step therapy exceptions, please call MedImpact 24 hours a day, 7 days a week, at 1-800-788-2949 or 711 (TTY). For cost sharing information for the outpatient prescription drug benefits in your specific plan, please visit: kp.org/kpic-ca-rx-ppo-ngf. For help in your preferred language, please see the Kaiser Permanente Insurance Company Notice of Language Assistance in this document. KPIC PPO NGF Table of Contents Informational Section................................................................................................................................2
    [Show full text]
  • Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes
    Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes Type 2 Diabetes ranges from predominantly insulin resistant with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance, American Diabetes Association, 2010. (ICD 9 code 250.0) Prevalence • 23.6 million Americans have diabetes – 7.8% of U.S. population. Of these, 5.7 million do not know they have the disease. • 1.6 million people ≥20 years of age are diagnosed with diabetes annually. • 90–95% of diabetic patients have Type 2 Diabetes. Manifestations Clinical of untreated diabetes • High blood glucose level • Excessive thirst • Frequent urination • Weight loss • Fatigue Oral • Increased risk of dental caries due to salivary hypofunction • Accelerated tooth eruption with increasing age • Gingivitis with high risk of periodontal disease (poor control increases risk) • Salivary gland dysfunction leading to xerostomia • Impaired or delayed wound healing • Taste dysfunction • Oral candidiasis • Higher incidence of lichen planus Other Potential Disorders/Concerns • Ketoacidosis, kidney failure, gastroparesis, diabetic neuropathy and retinopathy • Poor circulation, increased occurrence of infections, and coronary heart disease Management Medication The list of medications below are intended to serve only as a guide to facilitate the dental professional’s understanding of medications that can be used for Type 2 Diabetes. Medical protocols can vary for individuals with Type 2 Diabetes from few to multiple medications. ACTION TYPE BRAND NAME/GENERIC SIDE EFFECTS Enhance insulin Sulfonylureas Glipizide (Glucotrol) Angioedema secretion Glyburide (DiaBeta, Fluconazoles may increase the Glynase, Micronase) hypoglycemic effect of glipizide Glimepiride (Amaryl) and glyburide. Tolazamide (Tolinase, Corticosteroids may produce Diabinese, Orinase) hyperglycemia. Floxin and other fluoroquinolones may increase the hypoglycemic effect of sulfonylureas.
    [Show full text]
  • Diabetes Recommendations and Tier Coverage Chart
    DIABETES RECOMMENDATIONS AND TIER COVERAGE CHART The American Diabetes Association guidelines for 2020, recommend metformin as the preferred initial treatment for type 2 diabetes (T2DM) along with weight management and physical activity. In patients who have established ASVD or at high risk, CKD, or HF, a SGLT2i or GLP-1 receptor with proven efficacy is recommended independent of A1C. • ASCVD dominates: o GLP-1RA with proven CVD benefit (dulaglutide, liraglutide, injectable semaglutide) OR o SGLT2i with proven CVD benefit (canagliflozin, empagliflozin) if adequate eGFR • HF or CKD dominates: o SGLT2i with evidence of reducing HF and/or CKD progression (empagliflozin, canagliflozin, dapagliflozin) if adequate eGFR OR o If SGLT2i intolerant/contraindicated or eGFR is inadequate, then GLP-1RA with proven CVD benefit In individuals without established cardiovascular disease, pharmacological treatment should be patient-centered taking into account side-effects, cost, impact on weight, risk of hypoglycemia, and other patient preferences. For more detailed information regarding ADA recommendations for pharmacological agents to treat T2DM click here. The following chart is a list of oral and injectable diabetes medications listed by class with their respective A1C reduction and insurance coverage and/or coverage requirements for BCBS, HPHC, Tufts, TMP, and MassHealth. Tufts Medicare Medications BCBSMA HPHC Tufts Preferred MassHealth Biguanides A1C reduction: 1-1.5% metformin Tier 1 Tier 1;2 Tier 1 Tier 1 Covered Glucoghage (metformin) NC NC NC;Tier
    [Show full text]
  • Utah Medicaid Pharmacy and Therapeutics Committee Drug
    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review DPP-4 Inhibitor Products AHFS Classification: 68:20.05 Dipeptidyl Peptidase-4 Inhibitors Alogliptin (Nesina) Alogliptin and Metformin (Kazano) Alogliptin and Pioglitazone (Oseni) Linagliptin (Tradjenta) Linagliptin and Empagliflozin (Glyxambi) Linagliptin and Metformin (Jentadueto, Jentadueto XR) Saxagliptin (Onglyza) Saxagliptin and Dapagliflozin (Qtern) Saxagliptin and Metformin (Kombiglyze XR) Sitagliptin (Januvia) Sitagliptin and Metformin (Janumet, Janumet XR) Final Report November 2017 Review prepared by: Elena Martinez Alonso, B.Pharm., MSc MTSI, Medical Writer Valerie Gonzales, Pharm.D., Clinical Pharmacist Vicki Frydrych, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Assistant Professor University of Utah College of Pharmacy Michelle Fiander, MA, MLIS, Systematic Review/Evidence Synthesis Librarian Joanne LaFleur, Pharm.D., MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2017 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved 1 Contents List of Abbreviations .................................................................................................................................... 3 Executive Summary ...................................................................................................................................... 4 Introduction ..................................................................................................................................................
    [Show full text]
  • The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes
    Clinical Care/Education/Nutrition ORIGINAL ARTICLE The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes 1 JEAN-LOUIS CHIASSON, MD The recently developed class of 2 LISA NADITCH, MD ␣-glucosidase inhibitors has a unique FOR THE MIGLITOL CANADIAN UNIVERSITY mode of action; it blocks oligosaccharide INVESTIGATOR GROUP catabolism, delays carbohydrate diges- tion and absorption, and smooths and lowers postprandial plasma blood glu- cose peaks (6–9). Substantial evidence supports their use as monotherapy or ad- OBJECTIVE — To investigate the efficacy and safety of miglitol in combination with met- junct therapy for poorly controlled type 2 formin in improving glycemic control in outpatients in whom type 2 diabetes is insufficiently diabetes (5,10–14). Miglitol is the first controlled by diet alone. pseudomonosaccharide ␣-glucosidase in- RESEARCH DESIGN AND METHODS — In this multicenter, double-blind, placebo- hibitor derived from 1-deoxynojirimycin controlled study, 324 patients with type 2 diabetes were randomized, after an 8-week placebo and is structurally a glucose analog run-in period, to treatment with either placebo, miglitol alone, metformin alone, or miglitol plus (15,16). Its efficacy in monotherapy metformin for 36 weeks. The miglitol was titrated to 100 mg three times a day and metformin was (13,17) and in combination with sulfo- administered at 500 mg three times a day. The primary efficacy criterion was change in HbA1c nylureas (11) as a glucose-lowering agent from baseline to the end of treatment. Secondary parameters included changes in fasting and in type 2 diabetes has been shown in a postprandial plasma glucose and insulin levels, serum triglyceride levels, and responder rate.
    [Show full text]
  • Therapeutic Class Overview Meglitinides
    Therapeutic Class Overview Meglitinides Therapeutic Class • Overview/Summary: The meglitinides and the sulfonylureas are two classes of oral antidiabetic medications utilized in the management of type 2 diabetes that work by stimulating the release of insulin from pancreatic β-cells. While the meglitinide and sulfonylurea agents differ in chemical structure and act on different receptors, both medication classes act by regulating potassium channels in pancreatic β-cells, thereby increasing insulin secretion.1 The available meglitinides, nateglinide (Starlix®) and repaglinide (Prandin®), are Food and Drug Administration (FDA)-approved as adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Nateglinide and repaglinide are both available as single-entity agents, and repaglinide is also available as a fixed-dose combination product with metformin (PrandiMet®). Metformin, a biguanide, improves glucose tolerance in type 2 diabetics by lowering both basal and postprandial plasma glucose. Specifically, the actions of metformin result in decreased hepatic glucose production, decreased intestinal absorption of glucose, and improvement in insulin sensitivity via increased peripheral glucose uptake and utilization. The repaglinide/metformin combination product is FDA- approved for patients already treated with a meglitinide and metformin or for patients who have inadequate glycemic control on a meglitinide or metformin alone. Due to their mechanism of action and pharmacokinetic profiles, the meglitinides
    [Show full text]